Will digital therapeutics growth accelerate?

This blog post has been written by the person who has mapped the digital therapeutics market in a clean and beautiful presentation

The digital therapeutics market has reached a critical inflection point, transforming from experimental software into prescription-grade medical interventions with measurable patient outcomes.

With revenue jumping 26.7% in 2024 to reach $7.88 billion and projections pointing toward $56.76 billion by 2034, entrepreneurs and investors are recognizing that software-based therapies represent a fundamental shift in healthcare delivery rather than just another digital health trend.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

How big is the digital therapeutics market today and what was its 2024 growth?

The global digital therapeutics market generated $7.88 billion in revenue during 2024, representing a robust 26.7% year-over-year increase from the $6.22 billion recorded in 2023.

This growth acceleration marks a significant shift from experimental digital health tools to prescription-grade software therapies with measurable clinical outcomes. The market now supports 370 million monthly active users on prescription-grade platforms, compared to just 110 million in 2020.

Revenue concentration shows diabetes management commanding 29.36% of total market share, while mental health applications—particularly cognitive behavioral therapy solutions—capture approximately 45% of the connected care segment. These figures reflect the market's maturation beyond wellness apps toward evidence-based therapeutic interventions.

The 2024 growth surge stems from three key factors: expanded FDA approvals for prescription digital therapeutics, increased physician prescribing rates (62% among endocrinologists), and accelerated payer coverage adoption, with major insurers like UnitedHealth covering DTx for 43% of commercial members.

What does 2025 performance indicate about market momentum?

Early 2025 data projects revenue will reach $9.73 billion, representing a 23.5% growth rate that signals sustained but slightly moderating expansion compared to 2024's exceptional 26.7% surge.

This performance trajectory suggests the market is transitioning from early adoption to mainstream integration, with growth becoming more sustainable and predictable. The slight deceleration reflects natural market maturation rather than declining demand.

Key momentum indicators include accelerated venture capital deployment ($10.99 billion projected for 2025 versus $8.73 billion in 2024) and expanding reimbursement frameworks, including CMS's first-ever proposed Medicare billing codes for digital mental health devices.

Regional analysis shows Asia Pacific maintaining the fastest growth rates, while North America demonstrates the strongest revenue per user metrics, indicating geographic expansion is driving volume while developed markets focus on premium applications.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

If you want updated data about this market, you can download our latest market pitch deck here

What are the growth projections for the next 1, 5, and 10 years?

Market forecasts project steady acceleration with revenue reaching $11.86 billion in 2026, $21.1 billion by 2029, and $56.76 billion by 2034, based on a compound annual growth rate of 21.65%.

Which therapeutic areas drive the most revenue and growth?

Diabetes management dominates with 29.36% market share, generating approximately $2.31 billion in 2024 revenue through self-monitoring apps, medication adherence platforms, and continuous glucose monitor integration.

Mental and behavioral health represents the fastest-growing segment, with cognitive behavioral therapy applications capturing 45% of the connected care market. This includes prescription solutions for depression, anxiety, insomnia, and substance abuse disorders.

Obesity management emerges as the second-largest growth driver, fueled by integrated weight management programs combining behavioral coaching, nutrition tracking, and medication adherence support. These solutions typically generate $200-400 per patient annually in subscription revenue.

Cardiovascular health applications round out the top revenue segments, particularly solutions for hypertension monitoring, cardiac rehabilitation, and heart failure management that integrate with wearable devices and clinical workflows.

Specialty areas showing rapid expansion include respiratory health (asthma and COPD management), neurological conditions (migraine tracking, ADHD management), and oncology supportive care (symptom tracking, medication adherence).

What are current adoption rates among physicians, patients, and payers?

Physician adoption has reached majority levels in specialized fields, with 62% of U.S. endocrinologists regularly prescribing FDA-cleared digital therapeutics as of February 2024, compared to less than 20% in 2022.

Patient engagement shows strong momentum with 370 million monthly active users on prescription-grade platforms, indicating sustained usage beyond initial download. Average patient retention rates for prescription DTx exceed 60% at six months, significantly higher than consumer health apps.

Payer coverage expansion accelerated dramatically, with UnitedHealth providing DTx access to 43% of commercial members in 2024 versus just 18% in 2022. This represents coverage for approximately 15 million additional patients within a single major insurer.

Regional adoption varies significantly, with Germany leading global integration through its DiGA (Digital Health Applications) fast-track reimbursement program, covering over 40 approved DTx solutions for conditions ranging from tinnitus to depression.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

How does the current reimbursement landscape look and what changes are underway?

The reimbursement landscape achieved a historic breakthrough in 2025 with CMS proposing the first Medicare billing codes specifically for "digital mental health treatment devices," marking federal recognition of DTx as legitimate medical interventions.

The Access to Prescription Digital Therapeutics (PDT) Act, reintroduced in Congress in May 2025, seeks to establish explicit Medicare and Medicaid coverage pathways, potentially unlocking access for over 100 million government-insured patients.

Commercial insurers increasingly adopt value-based payment models, with successful examples including Omada Health's diabetes prevention program demonstrating 23% reduction in healthcare costs and Sleepio's insomnia therapy showing 28% lower overall healthcare expenses in economic evaluations.

Coverage consistency remains the primary challenge, with most insurers requiring evidence-development agreements rather than standard formulary inclusion. However, large employers are directly contracting DTx providers, bypassing traditional insurance limitations through self-funded health plans.

International markets show varying approaches: Germany's DiGA program provides immediate coverage upon regulatory approval, while France's PECAN assessment framework requires robust health economic data before reimbursement decisions.

If you want clear information about this market, you can download our latest market pitch deck here

What are the biggest barriers to adoption right now?

Regulatory uncertainty and inconsistent reimbursement policies represent the primary adoption barriers, with only 31% of FDA-cleared DTx receiving consistent payer coverage across major commercial plans.

Clinical integration challenges persist as healthcare providers struggle with EHR interoperability, workflow redesign requirements, and varying levels of digital literacy among clinical staff. Most DTx solutions require custom implementation processes rather than plug-and-play integration.

Evidence generation demands create significant barriers for emerging companies, as payers increasingly require peer-reviewed randomized controlled trials and real-world evidence studies costing $2-5 million per indication before coverage consideration.

Data privacy and cybersecurity concerns intensify as DTx solutions collect continuous biometric and behavioral data, requiring HIPAA compliance, FDA cybersecurity frameworks, and often additional state-level privacy protections.

Patient digital literacy and engagement sustainability challenge providers, particularly for older populations and chronic disease management where long-term adherence determines clinical outcomes.

What evidence exists for clinical efficacy and cost-effectiveness?

Propeller Health's inhaler adherence platform demonstrates quantifiable outcomes with 29 percentage point increases in medication adherence over 12 months and 54% reductions in rescue inhaler usage among asthma patients.

Sleepio's cognitive behavioral therapy for insomnia shows 76% of users achieving clinically meaningful improvement in sleep quality, with economic analysis revealing 28% lower overall healthcare costs compared to standard care.

Multiple randomized controlled trials validate CBT-based DTx effectiveness, including Zemedy's IBS solution demonstrating significant symptom reduction and WB001's depression therapy showing comparable efficacy to traditional counseling with greater accessibility.

Cost-effectiveness studies increasingly support DTx adoption, with diabetes management applications showing $1,200-2,400 annual savings per patient through reduced emergency visits and improved medication adherence.

Real-world evidence collection accelerates through partnerships with health systems, with companies like Biofourmis and Livongo publishing outcomes data from tens of thousands of patients demonstrating sustained clinical improvements and cost reductions.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

How competitive is the market and who are the leading players?

The competitive landscape spans established healthcare technology companies, specialized DTx developers, and pharmaceutical partnerships, with clear leaders emerging across therapeutic categories.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Are venture capital and private equity investments increasing or plateauing?

Venture capital investment in digital therapeutics reached $8.73 billion in 2024 and projects to $10.99 billion for 2025, representing a robust 25.9% compound annual growth rate that defies broader digital health funding declines.

Investment focus has shifted toward later-stage companies with proven clinical outcomes and regulatory approvals, with Series B and C rounds averaging $35-65 million compared to $15-25 million in earlier market phases.

Notable 2024 funding rounds include Click Therapeutics' $48.5 million Series C for smoking cessation applications, Pear Therapeutics' $64 million Series C for addiction treatment software, and Sidekick Health's €42 million debt financing for chronic disease management platforms.

Private equity interest intensifies as DTx companies demonstrate predictable revenue models through payer contracts and subscription-based patient engagement, with PE firms targeting companies with $10+ million annual recurring revenue.

Strategic pharmaceutical partnerships increasingly supplement venture funding, with companies like Otsuka partnering with Pear Therapeutics and Dassault acquiring Click Therapeutics to integrate DTx into traditional drug development and commercialization strategies.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Which regions show the fastest growth and most favorable conditions?

Asia Pacific demonstrates the fastest regional growth rates driven by vast populations, aging demographics, and favorable government digital health policies, particularly in China, Japan, and South Korea.

North America maintains the largest market share at 43-48% of global revenue, benefiting from mature regulatory frameworks, established physician adoption patterns, and comprehensive payer coverage through both commercial and government programs.

Europe leads in regulatory innovation through Germany's DiGA fast-track approval and reimbursement program, which has approved over 40 DTx applications since 2020 and provides immediate coverage upon regulatory clearance.

Emerging markets in Latin America and Southeast Asia show strong adoption potential due to physician shortages and limited traditional healthcare infrastructure, making DTx solutions attractive for chronic disease management and preventive care.

Regulatory harmonization efforts between FDA, EMA, and other authorities accelerate global market access, with companies increasingly pursuing simultaneous multi-regional approvals to capture first-mover advantages in high-growth markets.

What upcoming technological innovations could become major growth levers?

Artificial intelligence and machine learning integration enables hyper-personalized therapeutic interventions, with predictive algorithms optimizing treatment protocols based on individual patient responses and real-time biometric data.

Virtual reality therapies gain FDA approvals for specific conditions, including Luminopia's VR treatment for childhood amblyopia and EaseVRx for chronic pain management, establishing prescription-grade immersive therapeutics as a legitimate treatment modality.

Wearable device integration expands DTx capabilities through continuous monitoring platforms that combine Apple Watch, Fitbit, and medical-grade sensors to deliver real-time therapeutic interventions and clinical decision support.

Interoperability standards including HL7 FHIR and digital step therapy frameworks enable seamless DTx integration within electronic health records and payer systems, reducing implementation barriers and improving clinical workflow adoption.

Biomarker-driven therapeutics emerge through partnerships between DTx companies and diagnostic providers, enabling objective measurement of therapeutic efficacy and personalized treatment optimization based on genetic, metabolic, and behavioral markers.

Conclusion

Sources

1. Grand View Research - Digital Therapeutics Market Size
2. Precedence Research - Digital Therapeutics Market
3. Globe Newswire - Digital Therapeutics Market Analysis
4. Precedence Research - Connected Care Market
5. MedCity News - Digital Therapeutics Reimbursement
6. SAGE Journals - Digital Therapeutics Clinical Evidence
7. Quick Market Pitch - Digital Therapeutics Funding
8. AMCP - Prescription Digital Therapeutics Coverage